American journal of respiratory and critical care medicine

American journal of respiratory and critical care medicine
Audio Summaries

Every issue of American journal of respiratory and critical care medicine moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

24 audio summariesNLM Catalog

Specialties

American journal of respiratory and critical care medicine covers research in these specialties.

Recent summaries

The latest articles summarized from American journal of respiratory and critical care medicine.

Glucagon-Like Peptide-1 Agonists or Tezepelumab for Obesity-Associated Asthma: A Cohort Study.

Nov 20, 2026

This retrospective multi-institutional cohort study asked whether GLP-1-based medications (liraglutide, semaglutide, tirzepatide) offer respiratory benefits and weight loss comparable to the biologic tezepelumab in adults with obesity-associated, moderate-to-severe asthma without diabetes. Among 2,779 patients, tirzepatide initiators had a lower hazard of severe exacerbation than tezepelumab initiators (weighted HR 0.41), while semaglutide showed a similar hazard (weighted HR 0.99), and both tirzepatide and semaglutide led to faster >10% BMI reduction, less rescue inhaler use, and fewer respiratory encounters. The authors conclude that GLP-1-based therapies, particularly dual GLP-1/GIP agonists, may be comparable to biologic therapy in this population, though the observational design means randomized trials are needed to confirm these findings.

Charcot-Leyden crystals drive a localized inflammatory niche around mucus plugs in Allergic Bronchopulmonary Aspergillosis.

Nov 19, 2026

Charcot-Leyden crystals (CLCs), which form from eosinophil-derived Galectin-10, are common in pathologic mucus, but their functional role in disease was unclear. Using acute allergic bronchopulmonary aspergillosis (ABPA) as a model, the authors found that CLCs were a sensitive and specific marker of the disease and that CLC-containing mucus plugs were surrounded by localized type 2 inflammation. In a novel mouse model, CLC deposition was sufficient to cause persistent airway obstruction and inflammation, both reduced by a crystal-dissolving anti-Galectin-10 antibody, supporting CLCs as a biomarker, PET imaging target, and therapeutic target.

The Effect of Telemedicine-Based APAP Management on 24-Hour Ambulatory Blood Pressure in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.

Nov 16, 2026

This randomized non-inferiority trial asked whether telemedicine-based auto-adjusting positive airway pressure (APAP) management is as effective as standard in-person care for lowering 24-hour mean blood pressure over 3 months in patients with obstructive sleep apnea. Among 256 completers, the between-group difference (telemedicine minus in-person) was -0.59 mmHg in the intention-to-treat analysis and -1.21 mmHg in the completer analysis, with both upper confidence limits below the prespecified 1.5 mmHg margin. The authors concluded that telemedicine is noninferior to in-person management and may be a viable alternative delivery model for OSA-related blood pressure care.

Optimizing Sepsis Time Zero Definitions Through Associations between Antibiotic Timing and Mortality.

Nov 12, 2026

This study used electronic health record data from 145 U.S. hospitals (over 1.8 million encounters with suspected infection) to ask which SEP-1 organ dysfunction criteria best identify sepsis patients who are harmed by antibiotic delays. Antibiotic timing was associated with higher in-hospital mortality when time zero was defined by hypotension or lactate ≥4.0 mmol/L (with antibiotics at 1-3 vs. 0-1 hour), and by acute respiratory failure (with antibiotics at 3-6 vs. 0-3 hours among patients without hypotension or high lactate). The authors suggest these findings could help refine sepsis time zero definitions used for antibiotic urgency and performance measurement.

Systemic Inflammation in Bronchiectasis: Data from the EMBARC-BRIDGE Study.

Nov 7, 2026

This study asked whether systemic inflammation and circulating neutrophil function relate to disease severity and future exacerbations in bronchiectasis. Serum proteomic profiling of 487 patients in the international EMBARC-BRIDGE cohort revealed a dominant neutrophil-endothelial signature, with markers such as PR3, AZU1, MPO, ST2, and GDF-15 linked to greater severity, worse lung function, more symptoms, and often higher rates of severe exacerbations. Patients' blood neutrophils showed altered surface markers (reduced CD11b, increased CXCR2) and reduced basal degranulation, yet retained responsiveness to LPS stimulation, suggesting that bronchiectasis is marked by a systemic neutrophil and endothelial inflammatory state that is altered but still functionally responsive.

Development and Validation of a Pre-COPD Score to Predict Incident COPD.

Nov 6, 2026

This study tested whether a simple "pre-COPD score" could predict which people without airflow obstruction will go on to develop COPD. The researchers built the score in the Copenhagen General Population Study using smoking, symptoms, asthma, and spirometry markers (with PRISm weighted most heavily), then validated it in two other cohorts. The score showed good discrimination (AUC 0.76–0.88) and clearly stratified 5- to 10-year COPD risk, from about 1.5% in the low-risk group to 42% in the very high-risk group in the derivation cohort.

Reduced desaturation-based detection of sleep apnea events in self-identified Black individuals across two cohorts.

Nov 4, 2026

This study asks whether pulse oximetry-based desaturation criteria under-detect obstructive sleep apnea events in Black individuals, potentially because oximetry overestimates oxygen saturation in darker skin. Analyzing MESA and SHHS cohorts, the authors found that Black participants had about 20% lower proportions of airflow-limited events meeting the ≥4% desaturation criterion than White participants, while heart-rate-response-based detection (AHI-ΔHR6) was similar across groups. Desaturation-based measures also failed to predict cardiovascular events and mortality in Black individuals, whereas AHI-ΔHR6 did, suggesting heart-rate response as an oximetry-independent alternative for risk stratification.

As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline.

Nov 3, 2026

This American Thoracic Society guideline asks whether inhaled corticosteroid (ICS)-containing reliever therapy, either as ICS-formoterol or ICS plus SABA, should replace SABA-only reliever treatment in adolescents and adults with asthma across NAEPP steps 1-5. Using systematic reviews and GRADE assessments, the panel issued strong recommendations for as-needed ICS-SABA or ICS-formoterol over SABA-only therapy at steps 1-2 and for maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus SABA at steps 3-5. They also made conditional recommendations favoring ICS+SABA reliever over SABA reliever for patients on scheduled ICS-LABA, weighing prevention of severe exacerbations against SABA-only risks and ICS and systemic corticosteroid exposure.

Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials.

Nov 2, 2026

This post hoc analysis of the BOREAS and NOTUS trials asked whether dupilumab improves lung function in patients with COPD and type 2 inflammation. Over 52 weeks, dupilumab produced early and sustained gains in pre- and post-bronchodilator FEV1, FVC, FEV1/FVC, and FEF25-75 compared with placebo, with larger benefits in patients with higher baseline eosinophil counts or FeNO and benefits seen regardless of smoking status or emphysema.

Lung Allograft Function After Primary Graft Dysfunction in the Lung Transplant Outcomes Group Cohort.

Nov 2, 2026

Primary graft dysfunction (PGD) after lung transplant is linked to higher mortality, but it was unclear whether PGD harms long-term allograft function. In a prospective cohort of 2,419 recipients, the authors found that those with PGD reached lower maximum potential FEV1 (about 311 mL less) and were less likely to attain GLI-predicted FEV1. However, PGD was not associated with differences in the 5-year cumulative incidence of chronic lung allograft dysfunction (CLAD), including its obstructive or restrictive subtypes.

Listen to American journal of respiratory and critical care medicine

14-day free trial. Every new article, summarized in ~3 minutes.